ITGA2 and hepatocellular carcinoma: These findings not only confirm that ITGA2 may be one of the key drivers of lenvatinib resistance in HCC patients but also that the synergistic effect of ITGA2-specific small molecule inhibitors combined with lenvatinib provides new therapeutic strategies and a theoretical basis for future clinical applications and resistance reversal.